CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with ...
Hosted on MSN
LP(a): The match, the fuse, and the escape route
A new study finds that elevated levels of Lp(a) may increase the risk of death from cardiovascular disease in some patients by as much as 230%. (If Lp(a) is new to you, this THIS prior review article) ...
Lepodisiran, a long-duration, short-interfering RNA (siRNA), dramatically slashed Lp(a) levels in a small, phase I study presented this weekend at the American Heart Association (AHA) 2023 Scientific ...
Please provide your email address to receive an email when new articles are posted on . Investigational therapies to lower Lp(a) include antisense oligonucleotide therapies and small interfering RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results